New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:33 EDTARWRArrowhead receives approval to begin ARC-520 Phase 2a trial
Arrowhead Research announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520. The Hong Kong Department of Health issued a Certificate for clinical trial, allowing the company to proceed with its planned single-dose study of ARC-520 in two cohorts at two dose levels. A site initiation was completed and patient screening will initiate shortly. The company expects top line study results to be available in 3Q14. The Phase 2a study is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study to determine the depth and duration of hepatitis B surface antigen reduction after a single intravenous dose of ARC-520 in combination with entecavir in patients with chronic HBV infection. This study will be conducted in adult male and female patients aged 16 to 65 years, with immune active chronic HBV infection, HBV e antigen negativity, and ongoing entecavir therapy. The primary objective of the study is to evaluate the depth and duration of HBsAg decline in response to a single dose of ARC-520 in combination with entecavir. Secondary objectives include evaluation of safety and tolerability and pharmacokinetic measures.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
09:17 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
July 28, 2014
18:31 EDTARWROn The Fly: After Hours Movers
UP AFTER EARNINGS: Cognex (CGNX), up 16.4% after reporting second quarter results and third quarter revenue guidance above analyst expectations... HealthSouth (HLS), up 7.4% after reporting second quarter results and increasing fiscal 2014 EPS and Adjusted EBITDA guidance... Amkor Technology (AMKR), up 6.4%... Integrated Device (IDTI), up 7.6% after reporting first quarter results... Masco (MAS), up 4.8%. ALSO HIGHER: Darden Restaurants (DRI), up 4.6% following the company's announcement that chairman and CEO Clarence Otis will step down and the board will separate the chairman and CEO roles, appointing lead independent director Charles Ledsinger, Jr., as independent non-executive chairman... Arrowhead Research (ARWR), up 16.5% following positive comments made by CEO Christopher Anzalone, Ph.D. in an interview on CNBC. DOWN AFTER EARNINGS: Herbalife (HLF), down 11.5% after reporting disappointing second quarter results and giving guidance for the third quarter and fiscal 2014... Alliance Fiber Optic (AFOP), down 9.7%... Plum Creek Timber (PCL), down 2.8%... Eastman Chemical (EMN), down fractionally after reporting quarterly results. ALSO LOWER: TCP Capital (TCPC), down 3.1% after filing to sell $5.4M shares of common stock.
18:12 EDTARWRArrowhead Research up 15% following positive CEO comments on CNBC
17:56 EDTARWRArrowhead Research CEO says company has enough cash through Phase 3
Arrowhead Research CEO was speaking in a CNBC interview.
17:51 EDTARWRArrowhead Research CEO optimistic on Hep B trial data out in Q3
Arrowhead Research CEO speaking on CNBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use